# First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)

Source: https://onco.cc/trials/nct04725474/  
OnCo record `nct04725474` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Visugromab and Nivolumab in advanced solid tumours, run by CatalYm GmbH, active and no longer recruiting.

## Summary

First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER) is a phase 1/2 interventional study registered as NCT04725474 by CatalYm GmbH, with 199 participants enrolled, started 2020-12-09 and due to reach its primary completion in 2028-04-30. Interventions recorded: visugromab (CTL-002) and nivolumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04725474
- Phase: 1/2
- Setting: A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The "GDFATHER"-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).
- Sponsor: CatalYm GmbH
- Enrolled: 199

## Sources

- ClinicalTrials.gov NCT04725474: https://clinicaltrials.gov/study/NCT04725474

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Visugromab](https://onco.cc/drugs/visugromab/)
- companies: [CatalYm](https://onco.cc/companies/catalym/)

---
JSON: https://onco.cc/api/v1/entities/nct04725474.json